PMID- 25611567
OWN - NLM
STAT- MEDLINE
DCOM- 20160115
LR  - 20231213
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 30
IP  - 6
DP  - 2015 Jun
TI  - Prevalence of abnormal glycometabolism in treatment-naive patients with hepatitis 
      C virus infection in a Chinese Han population.
PG  - 1049-56
LID - 10.1111/jgh.12901 [doi]
AB  - BACKGROUND AND AIM: The hepatitis C virus (HCV) may promote pancreatic beta-cell 
      apoptosis-like cell death through a caspase 3-dependent pathway, initiating the 
      onset of type 2 diabetes mellitus (T2DM); however, the risk factors for 
      development of T2DM and other abnormal glycometabolic factors in HCV patients of 
      the Chinese Han ethnicity have been poorly explored. METHODS: A total of 947 
      patients Chinese Han patients with confirmed HCV infection were enrolled in a 
      multicenter study in order to examine the genetic and physiological parameters 
      associated with the onset of abnormal glycometabolic conditions, including T2DM 
      and prediabetes. RESULTS: HCV genotype 1b and host interleukin-28B CC genotype 
      were most commonly observed. A total of 145 (15.3%) patients were diagnosed with 
      T2DM and prediabetes. Elevated age, waist circumference, smoking duration, and 
      systolic and diastolic blood pressure were shown to increase risks for abnormal 
      glycometabolism. Liver dysfunction was shown to have positive correlations with 
      abnormal glycometabolism in HCV patients. Genome-wide association studies 
      indicated that certain genetic encoding inosine triphosphatase polymorphs 
      (rs6051702) were associated with elevated risks for abnormal glycometabolism. 
      Coupled with previous research data, it is likely that abnormal glycometabolism 
      may be a useful predictor of risk for poor response to antiviral therapies and 
      treatment-induced complications, such as anemia, in treatment naive patients. 
      CONCLUSIONS: Abnormal glycometabolism and other such complications of HCV and HCV 
      treatment may share critical metabolic and genetic pathways, providing 
      potentially novel targets for future antiviral therapies for treatment resistant 
      HCV genotypes.
CI  - (c) 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Rao, Huiying
AU  - Rao H
AD  - Peking University People's Hospital, Beijing Key Laboratory for Hepatitis C and 
      Immunotherapy for Liver Disease, Peking University Hepatology Institute, Beijing, 
      China.
FAU - Wei, Lai
AU  - Wei L
FAU - Li, Hong
AU  - Li H
FAU - Yang, Ruifeng
AU  - Yang R
FAU - Zhang, Haiying
AU  - Zhang H
FAU - Shang, Jia
AU  - Shang J
FAU - Chen, Hong
AU  - Chen H
FAU - Li, Jun
AU  - Li J
FAU - Xie, Qing
AU  - Xie Q
FAU - Gao, Zhiliang
AU  - Gao Z
FAU - Wang, Lei
AU  - Wang L
FAU - Wei, Jia
AU  - Wei J
FAU - Jiang, Jianning
AU  - Jiang J
FAU - Sun, Yongtao
AU  - Sun Y
CN  - CCgenos Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interleukins)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Asian People
MH  - China/epidemiology
MH  - Diabetes Mellitus, Type 2/*epidemiology/*etiology/genetics
MH  - Female
MH  - Genotype
MH  - Hepacivirus/genetics
MH  - Hepatitis C/*complications/*epidemiology/genetics/virology
MH  - Humans
MH  - Interferons
MH  - Interleukins/genetics
MH  - Male
MH  - Middle Aged
MH  - Prediabetic State/*epidemiology/*etiology/genetics
MH  - Prevalence
OTO - NOTNLM
OT  - glycometabolism
OT  - hepatitis C virus (HCV)
OT  - inosine triphosphatase (ITPA)
EDAT- 2015/01/23 06:00
MHDA- 2016/01/16 06:00
CRDT- 2015/01/23 06:00
PHST- 2015/01/12 00:00 [accepted]
PHST- 2015/01/23 06:00 [entrez]
PHST- 2015/01/23 06:00 [pubmed]
PHST- 2016/01/16 06:00 [medline]
AID - 10.1111/jgh.12901 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2015 Jun;30(6):1049-56. doi: 10.1111/jgh.12901.